TY - JOUR
T1 - Haemostatic variables during normal menstrual cycle A systematic review
AU - Knol, H. Marieke
AU - Kemperman, Ramses F. J.
AU - Kluin-Nelemans, Hanneke C.
AU - Mulder, Andre B.
AU - Meijer, Karina
PY - 2012/1
Y1 - 2012/1
N2 - For a number of haemostatic factors menstrual cycle variation has been studied. Such variation could have clinical implications for the timing of haemostatic testing in women. It was our objective to systematically review the literature about evidence for timing of haemostatic testing during menstrual cycle. We searched MEDLINE, EMBASE and the Cochrane library to identify studies that measured haemostatic variables [platelet function, von Willebrand factor (VWF), factor VIII (FVIII), factor IX (FIX), factor XI (FXI), factor XIII (FXIII), D-dimer, plasminogen activator inhibitor-I (PAI-1), tissue plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), alpha(2)-antiplasmin and fibrinogen] during normal menstrual cycle without hormonal contraceptives. Two investigators independently selected studies, and abstracted data in duplicate. We identified 1,046 studies of which we included 30 studies (25 longitudinal and 5 cross-sectional studies). All studies reported on haemostatic variables during menstrual cycle. Overall, most of the studies found no cyclic variation in VWF, FVIII, FXI, FXIII, fibrinolytic factors (PAI, t-PA, uPA, D-dimer and alpha(2)-antiplasmin) and fibrinogen. However, in studies where these variables showed any variation, they reached the lowest levels during menstrual and early follicular phase, especially for VWF, FVIII and platelet function tests. In conclusion, the optimal timing for haemostatic testing during menstrual cycle seems to be menstrual and early follicular phase.
AB - For a number of haemostatic factors menstrual cycle variation has been studied. Such variation could have clinical implications for the timing of haemostatic testing in women. It was our objective to systematically review the literature about evidence for timing of haemostatic testing during menstrual cycle. We searched MEDLINE, EMBASE and the Cochrane library to identify studies that measured haemostatic variables [platelet function, von Willebrand factor (VWF), factor VIII (FVIII), factor IX (FIX), factor XI (FXI), factor XIII (FXIII), D-dimer, plasminogen activator inhibitor-I (PAI-1), tissue plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), alpha(2)-antiplasmin and fibrinogen] during normal menstrual cycle without hormonal contraceptives. Two investigators independently selected studies, and abstracted data in duplicate. We identified 1,046 studies of which we included 30 studies (25 longitudinal and 5 cross-sectional studies). All studies reported on haemostatic variables during menstrual cycle. Overall, most of the studies found no cyclic variation in VWF, FVIII, FXI, FXIII, fibrinolytic factors (PAI, t-PA, uPA, D-dimer and alpha(2)-antiplasmin) and fibrinogen. However, in studies where these variables showed any variation, they reached the lowest levels during menstrual and early follicular phase, especially for VWF, FVIII and platelet function tests. In conclusion, the optimal timing for haemostatic testing during menstrual cycle seems to be menstrual and early follicular phase.
KW - Menstrual cycle
KW - haemostasis
KW - von Willebrand factor
KW - haemostatic variables
KW - VON-WILLEBRAND-FACTOR
KW - PLASMINOGEN-ACTIVATOR
KW - ORAL-CONTRACEPTIVES
KW - BLEEDING DISORDERS
KW - PLATELET-FUNCTION
KW - NORMAL WOMEN
KW - YOUNG-WOMEN
KW - FACTOR-VIII
KW - MENORRHAGIA
KW - PLASMA
U2 - 10.1160/TH11-07-0481
DO - 10.1160/TH11-07-0481
M3 - Review article
SN - 0340-6245
VL - 107
SP - 22
EP - 29
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 1
ER -